Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 19Carcinoma, Hepatocellular 18Stomach Neoplasms 17Nasopharyngeal Carcinoma 15Triple Negative Breast Neoplasms 13Esophageal Squamous Cell Carcinoma 13Breast Neoplasms 12Squamous Cell Carcinoma of Head and Neck 11Esophageal Neoplasms 11Uterine Cervical Neoplasms 10Colorectal Neoplasms 10Sarcoma 9Melanoma 6Recurrence 5Neoplasm Metastasis 5Lung Neoplasms 5Hodgkin Disease 5Cholangiocarcinoma 5Small Cell Lung Carcinoma 4Pancreatic Neoplasms 4Osteosarcoma 4Parkinson Disease 4, Autosomal Dominant Lewy Body 3Liver Neoplasms 3Glioblastoma 3Gestational Trophoblastic Disease 3Endometrial Neoplasms 3Biliary Tract Neoplasms 3Solid Tumor 2Rectal Neoplasms 2NSCLC 2

Interventions

Oxaliplatin 3Radiotherapy 2Folfox protocol 2Fluorouracil 2Capecitabine 2Bevacizumab 2Artesunate 2camrelizumab 1apatinib 1alectinib 1XELOX 1Trastuzumab 1Ocoxin 1Leucovorin 1Irinotecan 1Drug Therapy 1Chemoradiotherapy 1ABT-165 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Intestinal Neoplasms × camrelizumab × Clear all
NCT05193292 2022-01-14

Camrelizumab Combined With Trastuzumab and Chemotherapy in Patients With HER2-positive Advanced Colorectal Cancer

Fudan University

Phase 2 Unknown
77 enrolled
Gastrointestinal

Intestinal Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡